Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Empower your strategies with our Open-Angle Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions.

Open-angle glaucoma is a chronic eye condition characterized by increased intraocular pressure (IOP) that damages the optic nerve, leading to gradual and irreversible vision loss. It is the most common form of glaucoma and develops slowly over time, often without noticeable symptoms in the early stages. In open-angle glaucoma, the drainage system within the eye becomes less efficient over time, leading to a buildup of aqueous humor (fluid) and an increase in intraocular pressure. Elevated pressure damages the optic nerve, which transmits visual information to the brain, causing gradual vision loss. Risk factors include age (more common in individuals over 40), family history of glaucoma, high IOP, certain medical conditions (such as diabetes and hypertension), and certain ethnicities (African Americans have a higher risk). Early-stage, open-angle glaucoma often presents without noticeable symptoms or vision changes. As the condition progresses, peripheral vision loss (usually unnoticed at first) gradually advances to tunnel vision and, if untreated, can lead to complete blindness.

The Open-Angle Glaucoma drugs in development market research report provide comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope of Report

  • Therapeutics in Development: Covering 57 molecules, with 55 developed by companies and the rest by universities/institutes.
  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
  • Development History: Access the complete research and development history.
  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to buy

  • Holistic insights: Understand the broad spectrum of Open-Angle Glaucoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
  • Pipeline Exploration: Explore the detailed Open-Angle Glaucoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Open-Angle Glaucoma treatments for adaptable decision-making.
  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

What our clients have to say

More Reports

View More Reports